Jump to section
To reinvent disease management through early detection and precision intervention.
Freenome is a biotechnology company offering a biological analysis platform that uses molecular biology and machine learning to detect cancer with a routine blood draw. The platform trains on thousands of cancer-positive blood samples to recognise disease-associated patterns and help detect early-stage cancer, allowing clinicians to optimise treatments.
The company specialises in advanced computational biology, using machine learning to detect patterns among billions of circulating cell-free biomarkers. Freenome continues to focus on the development of its colorectal cancer test, potentially helping the 45 million people not currently up-to-date on colorectal cancer screening guidelines in the United States.
Following its 2022 funding round, the company surpassed the $1 billion funding mark. Freenome is set to accelerate the development of its platform, testing for additional cancers and furthering its blood test detection technology. It's also forming partnerships for R&D purposes, joining forces with health firms such as Geisinger to provide real world data that could help it detect multiple cancers.
Steph
Company Specialist at Welcome to the Jungle
Feb 2024
$254m
LATE VC
Dec 2021
$300m
SERIES D
This company has top investors
Riley Ennis
(CPO)Studied at Yale, Johns Hopkins and Dartmouth. Was a Thiel Fellow and co-founded Immudicon and Oncolinx.
Software Engineering
Marketing
Operations & Strategy